Safety Assessment of Cryopreserved Ovarian Tissue Transplantation in Patients Who Have Survived Sarcomas and Hematological Tumors

What this Trial Is About

Researchers are studying the presence or absence of primary tumor-specific markers in ovarian tissue of patients who have survived sarcomas or hematological cancers. The goal is to improve the safety of ovarian tissue transplantation by identifying highly sensitive molecular tests that detect malignant cells. This research aims to help patients overcome infertility caused by cancer treatments and improve their quality of life by offering the chance to have biological children. The study involves several steps: first, cryopreservation of ovarian tissue is performed. Next, tumor markers are identified in the patients' original tumor samples using histological, immunohistochemical, and molecular analysis. Then, these markers are searched for in the cryopreserved ovarian tissue. Finally, ovarian tissue autotransplantation is done if appropriate. This process is done across different patient groups, including those requesting cryopreservation, those with already cryopreserved tissue, and those requesting reimplantation. Participants will undergo tissue sampling and various laboratory tests to detect cancer cells in ovarian tissue over about one year. Researchers will evaluate detection rates of cancer cells and compare histological and molecular findings. Monitoring includes assessing ovarian contamination and disease-specific detection rates. The study is non-randomized and open-label, and participants are followed through the completion of the study period to assess safety and outcomes related to ovarian tissue transplantation.

Cryopreserved Ovarian Tissue Transplantation in Patients Who Have Survived Sarcomas and Hematological Tumors